Tianchen Biology completed a Series C financing round exceeding 200 million yuan.

36Kr learned from the official WeChat account of Tianchen Biotech that "Tianchen Biotech" announced the completion of over 200 million yuan in Series C financing. This round of financing was jointly led by Honghui Fund and existing shareholder Qiming Venture Partners, with follow - on investments from Linchuang Lanwan Fund, Beida Fund, and Zhenmai Fund. Existing shareholders such as Sanyi Capital and Shanxi Securities Innovation continued to increase their investments. The financing funds will be mainly used for the Phase III clinical trials and subsequent commercialization preparations of the core pipeline, the new - generation anti - IgE antibody LP - 003, as well as the Phase II clinical development of multiple indications for the world's first complement bifunctional antibody LP - 005, further consolidating Tianchen Biotech's innovation advantages in the fields of allergic and complement diseases.